Epidemiology and health related quality of life in hypoparathyroidism in Norway by Astor, Marianne et al.
Epidemiology and Health-Related Quality of Life in
Hypoparathyroidism in Norway
Marianne C. Astor, Kristian Løvås, Aleksandra Debowska, Erik F. Eriksen,
Johan A. Evang, Christian Fossum, Kristian J. Fougner, Synnøve E. Holte,
Kari Lima, Ragnar B. Moe, Anne Grethe Myhre, E. Helen Kemp,
Bjørn G. Nedrebø, Johan Svartberg, and Eystein S. Husebye*
Objective: The epidemiology of hypoparathyroidism (HP) is largely unknown. We aimed to de-
termine prevalence, etiologies, health related quality of life (HRQOL) and treatment pattern of HP.
Methods: Patients with HP and 22q11 deletion syndrome (DiGeorge syndrome) were identified in
electronic hospital registries. All identified patients were invited to participate in a survey. Among
patients who responded, HRQOL was determined by Short Form 36 and Hospital Anxiety and
Depression scale. Autoantibodies were measured and candidate genes (CaSR, AIRE, GATA3, and
22q11-deletion) were sequenced for classification of etiology.
Results: We identified 522 patients (511 alive) and estimated overall prevalence at 102 per million
divided among postsurgical HP (64 per million), nonsurgical HP (30 per million), and pseudo-HP (8
per million). Nonsurgical HP comprised autosomal dominant hypocalcemia (21%), autoimmune
polyendocrine syndrome type 1 (17%), DiGeorge/22q11 deletion syndrome (15%), idiopathic HP
(44%), and others (4%). Among the 283 respondents (median age, 53 years [range, 9–89], 75%
females), seven formerly classified as idiopathic were reclassified after genetic and immunological
analyses, whereas 26 (37% of nonsurgical HP) remained idiopathic. Most were treated with vitamin
D (94%) and calcium (70%), and 10 received PTH. HP patients scored significantly worse than the
normative population on Short Form 36 and Hospital Anxiety and Depression scale; patients with
postsurgical scored worse than those with nonsurgical HP and pseudo-HP, especially on physical
health.
Conclusions: We found higher prevalence of nonsurgical HP in Norway than reported elsewhere.
Genetic testing and autoimmunity screening of idiopathic HP identified a specific cause in 21%.
Further research is necessary to unravel the causes of idiopathic HP and to improve the reduced
HRQOL reported by HP patients. (J Clin Endocrinol Metab 101: 3045–3053, 2016)
Primary hypoparathyroidism (HP) is caused by a groupof heterogeneous diseases in which hypocalcemia
and hyperphosphatemia occur as a result of insufficient
PTH secretion or receptor dysfunction in target organs.
The most common etiologies among adults are surgical
damage to the parathyroid glands. Nonsurgical HP can be
either autoimmune or genetic (Table 1), but in many cases
the cause remains unknown, and is referred to as idio-
pathic HP.
Epidemiological studies on HP are sparse and mostly
cover certain subgroups. In Denmark, the prevalence of
postsurgical HP was 220 per million inhabitants, nonsur-
gical HP 23 per million, and pseudohypoparathyroidism
(PTH resistance; pseudo-HP) 11 per million (1–3), total-
ing 254 per million. An estimate among insured people
from the United States revealed that about 77 000 have
chronic HP of all causes (4), which translates into an ap-
proximate prevalence of 250 per million. In Japan and
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Israel, theprevalencenumbersof idiopathicHPwere7and
9 per million, respectively, and of pseudo-HP in Japan 3
per million (5, 6).
Patients with pseudo-HP and vitamin D resistance have
elevated PTH, in contrast to classical HP. The clinical pic-
ture in pseudo-HP and vitamin D resistance is equal to
other forms of HP and is therefore included as a subgroup
of HP. Autosomal dominant hypocalcemia (ADH) (7) is
probably the most common genetic cause of HP, usually
caused by an activating mutation in the calcium-sensing
receptor (CASR), termed ADH type 1, or rarely in guanine
nucleotide binding protein, alpha 11 (GNA11), termed
ADH type 2 (8). Occasionally, CASR mutations induce
polyuria and hypokalemic alkalosis, called ADH with
mild Bartter syndrome type 5. The severity of ADH is
highly variable, and asymptomatic patients and those who
exhibit mild symptoms can often go undiagnosed.
Autoimmune HP is mainly seen as part of autoimmune
polyendocrine syndrome type 1 (APS-1), in which it is
present in about 80% (9, 10). About one-half of the APS-1
patients with HP have autoantibodies against NACHT
leucine-rich repeat protein 5 (NALP5), an intracellular
protein with unknown function highly expressed in para-
thyroid tissue (11). Autoantibodies against interferon
omega (IFN-) can be detected in nearly all APS-1 patients
regardless of organ involvement (12). Autoantibodies that
activate CaSR have also been described as an autoimmune
cause of HP (13).
HP may occur as part of various syndromes, most com-
monly the 22q11 deletion syndrome (DiGeorge syn-
drome). The prevalence of hypocalcemia among patients
with this syndrome varies from 17% to 60% in different
reports (14), and most have PTH levels below or in the low
reference range (15) due to underdeveloped parathyroid
glands. Only a minority requires treatment for chronic
hypocalcemia, and only 7% of those with DiGeorge syn-
drome were diagnosed based on hypocalcemia and HP in
a Norwegian national survey (16).
The conventional treatment of HP is calcium and active
vitamin D supplementation to alleviate symptoms of hy-
pocalcemia. To ensure normal level of 25-hydroxyvitamin
D, many patients also need supplementation with calcif-
erol because treatment with calcitriol or alphacalcidiol
does not affect the 25-hydroxyvitamin D status. Calciferol
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Table 1. Causes of Hypoparathyroidism
Cause Gene (When Indicated) Reference
Postsurgical and/or Following Radioactive Iodine Thyroid Ablation
Autoimmune
Isolated
Component of APS-1 AIRE/21q22.3 (9, 10)
Genetic
Isolated
ADH types 1 and 2 CASR/3q21.1, GNA11/19p13.3 (7, 40)
PTH mutations PTH/11p15
GCMB mutations GCMB/6p24.2 (41)
X-linked recessive SOX3/Xq26-27
As part of syndromes
DiGeorge (22q11.2 deletion syndrome) TBX1/22q11 (14, 42)
HDR syndrome GATA3/10p13-14 (43)
Hypoparathyroidism-retardation-dysmorphism syndrome (Sanjad-Sakati syndrome)
and Kenny-Caffey syndrome
TBCE/1q42.3, FAM111A/11q12.1a (44–46)
Mitochondrial associated (Kearns-Sayre and others)
Stormorken’s syndrome STIM1/11p15.4 (47)
Target organ resistance
Pseudohypoparathyroidism types 1 and 2 GNAS,STX/20q13.3 (48)
Blomstrand chondrodysplasia PTHR1/3p22-p21.1
Hypomagnesemia TRPM6/9q21.13b
Vitamin D-dependent rickets VDR/12q13.11 (type 2a)
Idiopathic
Miscellaneous
Infiltrative disorders (hemochromatosis, thalassemia, Wilson’s disease, metastasis)
a Kenny-Caffey syndrome type 2.
b Hypomagnesemia from TRPM6 mutations is typically accompanied by secondary hypocalcemia, but severe hypomagnesemia of any cause can
give target organ resistance.
3046 Astor et al Hypoparathyroidism in Norway J Clin Endocrinol Metab, August 2016, 101(8):3045–3053
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 15 December 2016. at 06:53 For personal use only. No other uses without permission. . All rights reserved.
is probably important for several cellular processes be-
cause intracellular hydroxylation to active vitamin D oc-
curs in many different cells (eg, bone, gut, prostate). The
well-known neuromuscular problems accompanying vi-
tamin D insufficiency, together with proposed association
of vitamin D insufficiency to a number of different con-
ditions such as cancer and diabetes mellitus is a reasonable
argument to ensure adequate vitamin D status also in HP
patients (17). Higher doses of calciferol can also be used
instead of active vitamin D, and was the treatment of
choice before active vitamin D became available. Calcif-
erol increases the risk of prolonged hypercalcemia, and is
now recommended for treatment of HP only if active vi-
tamin D is unavailable.
To minimize the hypercalcuria and hyperphosphatemia
following treatment with potent vitamin D analogues, se-
rum calcium should be kept in the low normal range or
slightly below. Undertreatment can lead to complications
such as convulsions and arrhythmias, and overtreatment to
tissue calcification with risk of kidney failure (18). PTH
replacement therapy is not approved in Europe, but is advo-
cated as a treatment option for patients who are difficult to
manage on conventional therapy (17, 19) and since January
2015 recombinant human PTH (1–84) has been approved
in the United States for the treatment of HP.
Given the scarcity of epidemiological data and the
unique possibility to obtain nationwide data in Norway,
we aimed to establish the epidemiology, etiology, and
quality of life (QOL), and to map current treatment mo-
dalities in a nation-wide survey of HP.
Materials and Methods
Patients and design
We aimed to identify all living patients with HP in Norway
who had been registered in an electronic hospital registry because
we assumed that the vast majority of the patients would have
been admitted to specialist care at least at the time of diagnosis.
The health care system in Norway consists of four regional health
authorities that own the health trusts (there are19 somatic health
trusts) that are responsible for the hospitals in each region (vary-
ing from one to six hospitals in each trust). Invitations to par-
ticipate in the study were sent to all but two health trusts com-
prising five hospitals that were considered too small and lacked
endocrinology departments. The research department in two of
the health trusts declined participation (seven hospitals), and one
health trust (four hospitals) and three single hospitals did not
respond to our request. Thus, we searched the inpatient and
outpatient registries at departments of medicine, surgery, and
pediatrics in 35 of 54 hospitals, including all the tertiary
and most of the secondary endocrine centers. Altogether, 80% of
the Norwegian population was covered. In addition, the survey
was advertised through the Norwegian HP patient association.
The inclusion period was from October 2010 through Sep-
tember 2013. The search criteria were the International Classi-
fication of Diseases, version 10 (ICD10), codes E20.0–9 (HP),
E21.4 (other specified disorders of parathyroid gland), E89.2
(postsurgical HP), and D82.1 (DiGeorge syndrome). In two of
the university hospitals, the search also included codes E83.5
(disorders of calcium metabolism), R29.0 (tetany), P71.0–9
(transitory neonatal disorders of calcium and magnesium me-
tabolism), and the following ICD9 codes; 252.1, 252.8, 252.9
(disorders of the parathyroid gland); 275.40, 275.41m and
275.49 (disorders of calcium metabolism); 781.7 (tetany); 775.4
(hypocalcemia and hypomagnesemia in the newborn) and
279.11 (DiGeorge syndrome).
Medical records were reviewed and the diagnosis of HP was
verified by an endocrinologist in each case. The diagnostic cri-
teria were one of the following: 1) serum calcium below reference
range with simultaneously low or inappropriately normal PTH,
2) serum calcium below reference range with simultaneously
high PTH and normal renal function (pseudo-HP), or 3) criterion
one plus need of permanent treatment for more than 1 year when
HP was due to surgery or DiGeorge syndrome. Patients who
fulfilled the inclusion criteria were invited to participate in the
study and to complete a questionnaire including time of diag-
nosis and symptoms, treatment, and cause of the disease (if
known), the Short Form 36 (SF-36) and Hospital Anxiety and
Depression scale (HADS). Blood and urine samples were col-
lected. Nonrespondents received a second invitation and a phone
call to ask for willingness to participate. All participants or their
guardians gave written informed consent. The regional commit-
tee for medical and health research ethics of Western Norway
approved the study, and separate approval was given at each
participating hospital trust’s research department.
Blood and urine analyses
Serum was analyzed for total calcium, albumin, phosphate,
magnesium, creatinine, thyroid-stimulating hormone and free thy-
roxine. Absolute estimated glomerular filtration rate (eGFR) was
calculated based on measured creatinine and calculated body sur-
face according to the formula: Calculated eGFR (Modification of
Diet in Renal Disease formula)  (0.20247  height (m)0.725 
weight (kg)0.425)/1.73, where the Modification of Diet in Renal
Disease formula is175 (s-Creatinine/88.4)1.154  (age)0.203 
0.742 (if female). Albumin-corrected calcium was calculated from
the formula: serum calcium (mmol/liter)  0.02  (40 – measured
serum-albumin [g/liter]). In spot urine, creatinine and calcium per
mmol creatinine were assayed. Assays of autoantibodies against
NALP5 and interferon omega (IFN-) were performed using ra-
dioligand binding assay (20). CaSR antibodies were tested using
immunoprecipitation (21). All the nonsurgical patients and a ran-
dom sample of 20 postsurgical patients were tested for CaSR an-
tibodies. All patients with available blood samples (n  251) were
analyzed for antibodies against NALP5 and IFN-.
Sequencing of genes was carried out by Sanger sequencing.
The multiplex ligation-dependent probe amplification technique
was used for analysis of large deletions/duplications. DNA was
purified from blood using QIASymphony SP Midi Kit. Sequenc-
ing of the CASR gene and 22q11 were performed in all patients
with idiopathic HP. GATA3 was sequenced to identify one pa-
tient with the syndrome of hypoparathyroidism, sensorineural
deafness, and renal disease (HDR), and AIRE was sequenced in
one patient with NALP5 autoantibodies.
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Questionnaires
SF-36 is a 36-item QOL questionnaire with response alter-
native scores 1–6 for each item. A scoring algorithm transforms
the raw score to a score from 0 to 100, where a high score in-
dicates better health-related QOL (HRQOL). Eight scales are
calculated: perception of physical functioning (PF), role limita-
tions due to physical problems (RP), bodily pain, general health
(GH), vitality (VT), social functioning, role limitations due to
emotional problems, and mental health. Missing data were re-
placed by the mean scores of the completed items in the same
scale if at least half of the items in the actual scale were answered.
HADS is a 14-item questionnaire, seven for anxiety and seven for
depression. Scores are 0–3 for each item, and lower scores are
favorable. If a single item from a subscale was missing, the data
were replaced by using the mean of the remaining six items. If
several items were missing, the subscale was discarded. Nor-
wegian normative data are available for both SF-36 (22) and
HADS (from the Health Study of Nord-Trøndelag 1995–97,
HUNT II) (23).
Statistics
Norway’s population in 2012 (4 985 870 inhabitants) was
used to calculate prevalence (Statistics Norway) (24). Two sam-
ple t tests and the Mann-Whitney U test were used for continuous
data that were normally and not normally distributed, respec-
tively. One-way ANOVA was used to determine differences be-
tween the means of three or more independent groups, with post
hoc analyses by Fisher’s least significance difference test or
Games-Howell when appropriate. Data are presented as median,
unless specified. A significance level at 0.05 was chosen for all
tests. Pearson’s  was calculated for bivariate correlations.
Results
Patient identification and epidemiology
The initial search in two hospital registries using ex-
tended search criteria yielded more than 2000 hits, but
only 132 were verified as HP. For subsequent searches, all
ICD9 codes and three ICD10 codes (E83.5, R29, and
P71.0–9), were omitted. According to the results from
these two centers, using the narrower search criteria we
might miss approximately 8% of the HP patients. Even the
narrowed search criteria revealed a coding practice that
could not alone be trusted to identify patients. The erro-
neous coding was mostly attributed to hypocalcaemia of
other causes, such as critical illness, malignancy, renal fail-
ure, and transient HP after surgery.
Altogether 522 patients were identified, of whom 511
were alive at the end of the registration period, yielding an
overall prevalence of 102 per million, of whom 94 and 8
per million were genuine and pseudo-HP, respectively.
Postsurgical HP comprised 321 individuals (64 per mil-
lion) and nonsurgical HP 151 individuals (30 per million,
pseudo-HP excluded). There were large regional varia-
tions in postsurgical HP prevalence (Table 2), which ac-
counts for most of the variation in overall HP prevalence.
Among the nonsurgical HP patients, the largest subgroup
was idiopathic (n  67, 44%), whereas 85 had genetic or
autoimmune HP, of which ADH (n  31, 21%), APS-1
(n  25, 17%), and DiGeorge syndrome (n  23, 15%)
were most common. Four patients had HDR, one had
vitamin D-dependent rickets type 1, and one had Stor-
morken’s syndrome (Table 3). The patient with vitamin
D-dependent rickets is not included in the further analysis,
but is included in tables for completeness. Eight percent of
the identified patients with DiGeorge syndrome had per-
manent treatment for HP of more than 1 year duration.
Ninety percent of the patients were identified through
search of hospital registries, whereas 10% were identified
from other sources, in particular the patient organization.
National survey
Two hundred and eighty three (55%) agreed to partic-
ipate (median age, 53 years [range, 9–89]; 75% females).
The sex and age distribution of the identified patients and
respondents were similar, but postsurgical HP was slightly










Inhabitants 4 985 870 2 785 259 1 041 886 687 968 470 757
HP and pseudo-HP n (prev/100 000) 511 (10.2) 256 (9.2) 117 (11.2) 72 (10.5) 66 (14.0)
Postsurgical n (prev/100 000) 321 (6.4) 183 (6.6) 47 (4.5) 51 (7.4) 40 (8.5)
Nonsurgical n (prev/100 000) 148 (3.0) 54 (1.9) 59 (5.7) 17 (2.5) 18 (3.8)
Idiopathic 64 (1.3) 31 (1.1) 14 (1.3) 8 (1.2) 11 (2.3)
APS-1 25 (0.5) 9 (0.3) 9 (0.9) 3 (0.4) 4 (0.8)
ADH 31 (0.6) 4 (0.1) 26 (2.5) 1 (0.1) 0
HDR 4 (0.08) 1 (0.04) 3 (0.3) 0 0
DiGeorge 23 (0.5) 8 (0.3) 7 (0.7) 5 (0.7) 3 (0.6)
Othera 1 1 0 0 0
PseudoHP (prev/100 000) 41 (0.82) 19 (0.7) 10 (1.0) 4 (0.6) 8 (1.7)
Vitamin D-resistant rickets 1 1
Abbreviations: prev, prevalence; RHA, regional health authorities.
a One patient had HP from Stormorken’s syndrome.
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more common among the respondents (Table 3). Patients
with postsurgical HP, ADH, and APS-1 had a response
rate at about 60%, whereas the response rates for patients
with idiopathic HP, pseudo-HP, and DiGeorge syndrome
were 35–40%.
Etiology of nonsurgical HP
Positive IFN- autoantibodies were found in 16 pa-
tients, of whom 15 had APS-1 (100%). One had postsur-
gical HP and had previously been treated for malignant
thymoma and myasthenia gravis. NALP5 autoantibodies
were detected in 11 patients, of whom seven had known
APS-1 (median titer, 822; range, 787–1555; cutoff, 65).
One patient with high titer (1020) was diagnosed with
idiopathic HP at age 22; all other tested antibodies were
initially negative, including IFN-. However, sequencing
of AIRE confirmed two known disease-causing mutations
(c.879GA and c.967_979del) consistent with APS-1
(10), and a new serum sample taken 2 years after the first
was now clearly positive for IFN-. Three patients with
positive NALP5 autoantibodies and no evidence of APS-1
had low titers (indices, 66–161). One patient had positive
CaSR autoantibodies, although only a slightly elevated
index (2.69; cutoff value, 2.26). This patient was later
diagnosed with DiGeorge syndrome. Seven patients
(21%) formerly classified as idiopathic HP were reclassi-
fied after genetic testing. Four had activating mutations in
CASR (ADH), one had DiGeorge syndrome, one had the
HDR syndrome, and one APS-1 (see the previous section).
Treatment and follow-up
Calcium supplementation was used by 198 (70%), vi-
tamin D by 267 (94%) and active vitamin D formulations
by 237 (84%) (Table 4). About half (n  136, 48%) used
either ergocalciferol (39%) or cholecalciferol (61%), of
which 102 (75%) were used in combination with active
formulations of vitamin D. Eleven used ergocalciferol in
high doses as the only vitamin D source. Ten patients were
treated with subcutaneous PTH, of whom three received
1–34 injections, five received 1–84 injections, and two
received 1–84 continuous infusions by pump. There was
no significant difference in types of medication used by
postsurgical, nonsurgical, or pseudo-HP patients, except
treatment with PTH; nine of these were postsurgical and
one nonsurgical. Median albumin corrected serum cal-
cium was below the reference range (2.08 mmol/liter; ref-
erence range, 2.20–2.55), whereas the median urine cal-
cium value was slightly above the reference range (0.51
mmol/mmol creatinine; reference range, 0.04–0.50) (Ta-
ble 4). Postsurgical HP had significantly higher albumin
corrected serum calcium and serum magnesium than non-
surgical HP patients (P  .002 and P  .007, respectively),
whereas serum phosphate levels were similar. Eighteen
percent had kidney failure (eGFR 60 ml/min), of whom
98% had an eGFR level greater than 30. The median eGFR
was 80.8 (14.6–215.7) ml/min. Patients with both post-
surgical and nonsurgical HP had significantly higher cal-
cium excretion (P  .001 and P  .003, respectively) and
postsurgical patients also had lower eGFR (P  .04) than
pseudo-HP patients.
The nonsurgical patients were younger than the post-
surgical HP patients both at the time of diagnosis (median
22 vs 40 years) and at the time of the study (median 48 vs
56 years). Pseudo-HP patients were youngest both at time
of diagnosis (median, 12 years) and at the time of study
(median, 32 years). Overall, the median age at diagnosis
was 36 years (range, 0–81). Most (70%) were diagnosed
with HP within the first 6 months from presentation of
hypocalcemic symptoms, but 17% were diagnosed be-
tween 2 and 5 years after the first symptoms. In 9%, the
diagnosis was delayed more than 5 years. Many patients
with nonsurgical HP were diagnosed late; 14% between 2
and 5 years and 14% more than 5 years after symptom
debut, as opposed to postsurgical HP (corresponding
numbers were 5% and 6%, respectively). Among patients
with pseudo-HP, 19% and 31% were diagnosed between
2 and 5 years and more than 5 years after symptom debut,
respectively.
Most of the patients (64%) were diagnosed by an in-
ternist, endocrinologist, or pediatrician, but 15% were
diagnosed by a general practitioner and 21% by others. A
higher percentage of the postsurgical patients were diag-
nosed by others (24%), primarily a surgeon, but also 16%
of nonsurgical patients and 7% of pseudo-HP patients
were diagnosed by noninternists, mostly neurologists.
The majority (82%) had their serum calcium levels as-
sessed every 6 months or more frequently. A higher per-
centage of patients in the surgical group (69%) than the






Age, y (range) 51 (4–91) 53 (9–89)
Female 381 (73%) 212 (75%)
Postsurgical 329 (63%) 197 (70%)






Other causes 2a 2a
Pseudo-HP 41 (8%) 16 (6%)
a One patient with vitamin D-dependent rickets (excluded from further
analysis) and one with Stormorken’s syndrome.
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nonsurgical (44%) and the pseudo-HP group (53%) re-
ported that urine calcium never had been measured.
QOL and working ability
The SF-36 and HADS scores are given in Table 5 as
mean  SD compared with respective Norwegian norma-
tive data (22, 23). HP patients had significantly lower
SF-36 scores than the normative population in all eight
dimensions, but pseudo-HP patients in only three of eight
dimensions (RP, VT, social functioning). Overall female
patients scored worse than male patients for PF (P  .03)
and VT (P  .03), whereas patients with postsurgical HP
scored worse than nonsurgical for RP (P  .002), bodily
pain (P  .03) and VT (P  .04) and worse than
pseudo-HP for PF and GH (both P  .03).
HP patients displayed significantly higher symptom
score for anxiety, depression, and total HADS score
than normative Norwegian population. The postsurgical
group scored worse on depression than nonsurgical (P 
.02). Thirty-eight percent had anxiety scores of at least 8,
and 26% had depression score of at least 8, indicative of
clinical significant anxiety and depression. Nine of sixteen
patients (56%) with pseudo-HP had anxiety scores of at
least 8. Gender did not affect the HADS scores
significantly.
No correlation between SF-36 or HADS scores (overall
and subgroups) were found, either with corrected calcium
levels or serum magnesium levels. However, there was a
weak negative correlation between PF and serum magne-
sium (Pearson’s , –0.2; P  .02) in postsurgical HP
patients.
Working ability
Forty percent received permanent or temporary social
security benefits (SSB) (Table 4). Among the general pop-
ulation in Norway aged 18–66 years, the proportion of
permanent SSB is about 10% and temporary SSB about
4% (24).
Discussion
We found an overall prevalence of HP in Norway less than
half the prevalence recently established in Denmark (1–3)
Table 4. Basal Characteristics, Laboratory Results, and Treatment Among Respondents (Median-Range)




(n  16) P Value
Age (y), median (range) 53 (9–89) 56 (20–89) 48 (10–72) 32 (9–60) .002a
.001b
Female, n (%) 212 (75) 161 (82) 40 (58) 10 (63) .001a
BMI (kg/m2), median (range) 25 (14–60) 25 (15–60) 25 (14–47) 25 (17–34) NS
SSB
Retirement pension, n (%) 51 (18) 46 (23) 5 (7) 0 NS
Permanent SSB, n (%) 72 (25) 53 (27) 15 (22) 4 (25) NS
Temporary SSB, n (%) 42 (15) 33 (17) 9 (13) 0 NS
Laboratory Results Ref. Range/Cut off
Corrected s-calcium (mmol/liter) 2.08 (1.47–2.84) 2.09 (1.61–2.69) 2.00 (1.68–2.84) 2.14 (1.47–2.25) .002a 2.20–2.55
s-Magnesium (mmol/liter) 0.83 (0.64–1.22) 0.83 (0.64–1.22) 0.80 (0.65–1.00) 0.89 (0.69–1.10) .008a
.02c
0.71–0.94
s-Phosphorus (mmol/liter) 1.29 (0.76–2.55) 1.29 (0.77–2.55) 1.32 (0.76–2.27) 1.38 (0.99–2.05) NS 0.75–1.50a
TSH (mIE/liter) 1.22 (0.01–14.20) 0.69 (0.01–14.20) 1.83 (0.04–5.42) 2.35 (0.01–6.86) NS 0.40–4.50
FT4 (pmol/liter) 19.3 (9.3–39.6) 20.7 (11.0–39.6) 16.6 (9.3–23.6) 15.1 (10.1–24.2) .001a 9.5–22.0
.001b
Creatinine (mol/liter) 75.0 (33–247) 76.0 (34–247) 74.0 (44–168) 60.5 (33–102) .03c Male: 60–105
Female: 45–90
eGFR (ml/min) 80.8 (14.6–215.7) 78.6 (14.6–181.5.) 86.3 (30.4–152.0) 105.1 (52.6–215.7) .04b 90






Calcium (mg/day) 1000 (167–10 000) 1000 (167–10 000) 1000 (250–4000) 1000 (500–2000) NS 70
Calcitriol (g/day) 0.75 (0.13–4.00) 0.75 (0.13–4.00) 0.60 (0.25–2.00) 1.00 (0.75–1.40) NS 40
Alphacalcidiol (g/day) 1.50 (0.25–6.00) 1.50 (0.25–6.00) 1.50 (0.40–5.00) 1.25 (0.50–4.00) NS 44
Ergocalciferol (D2) (U/day) 4286 (1286–210 000) 4286 (1286–150 000) 4286 (2143–210 000) 3214 (2143–4286) NS 19
Cholecalciferol (D3) (U/day) 800 (200–8000) 800 (200–8000) 800 (400–2400) 800 (800–800) NS 29
Magnesium (mg/day) 300 (120–1200) 300 (120–1200) 300 (120–1200) 300 (120–375) NS 34
PTH use (n) 10 9 1 0 4
Different reference ranges for different gender and age groups for s-phosphorus and s-creatinine. The results calculated for both sexes and all age
groups combined.
Abbreviations: FT4, free thyroxine; NS, not significant.
a Statistical significant difference between postsurgical and nonsurgical group.
b Statistical significant difference between postsurgical and pseudo-HP group.
c Statistical significant difference between nonsurgical and pseudo-HP group.
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and the United States (4). This difference mainly reflects
fewer with postsurgical HP in our study because the prev-
alence of nonsurgical HP was higher than in Denmark (2).
Nonsurgical HP was most common in Western Norway,
where ADH in a few large families (25) and APS-1 ac-
counted for the difference. These differences could be gen-
uine or due to underdiagnosing in other regions. Higher
prevalence of idiopathic and pseudo-HP were found in the
Norwegian cohort than in studies in Japan (5), but similar
to that found in Denmark (3) and in Israel (6).
IFN- autoantibodies were detected in all the APS-1
patients, but also in one postsurgical patient, who had
thymoma-associated myasthenia gravis, in which IFN-
autoantibodies are common (26). In concordance with
earlier studies (11), NALP5 autoantibodies were detected
in 50% of the patients with previously known APS-1. One
patient with a high titer of NALP5 autoantibodies, diag-
nosed as idiopathic HP 39 years previously tested negative
for IFN- autoantibodies, but sequencing of AIRE con-
firmed APS-1, and a repeat sample 2 years later was clearly
positive also for IFN- autoantibodies.
Despite testing for underlying causes, about one-third
of nonsurgical patients remain idiopathic, which may con-
ceal hitherto unidentified forms of HP. The medical his-
tory and clinical vigilance can to some extent guide the
clinician to the underlying cause, but in many cases the
cause is not obvious. According to our results, it here
seems reasonable to test for ADH, APS-1, and DiGeorge
syndrome. Antibodies against IFN- and NALP5 are ex-
cellent markers of APS-1 (11, 27, 28). Testing for anti-
bodies against the CaSR among patients with idiopathic
HP does not seem justified based on our results.
We believe that the search for ADH among patients
with idiopathic HP is important because these patients
should receive treatment with calcium and vitamin D only
if the disease is symptomatic. The treatment increases hy-
percalcuria and risk of kidney failure more than other
forms of HP (7). Symptomatic patients should be treated,
but only to alleviate symptoms, not to restore normocal-
cemia, as low dosages of calcitriol results in less frequent
renal calcifications (7). Diagnosis of APS-1, DiGeorge, or
other syndromes is also of great importance because other
components of these disorders need to be identified and
treated early to avoid untimely morbidity and mortality.
Most of the patients in the Norwegian HP population
received conventional calcium and active vitamin D sup-
plementation, which was associated with a high propor-
tion of kidney failure, indicating a need for improvement
of the therapy.
Our study corroborates earlier studies showing re-
duced HRQOL among HP patients (29–31), especially
among patients with postsurgical HP who also had sig-
nificantly lower SF-36 scores than Norwegian patients
with Addison’s disease in six of eight dimensions and con-
genital adrenal hyperplasia in five of eight dimensions (32,
33). One plausible explanation could be a higher propor-
tion of absolute PTH depletion or related to the cause of
surgery (ie, Graves’ disease or thyroid cancer), but there is
no correlation to the calcium levels. Receptors for PTH are
found in several tissues, including the central nervous sys-









HP and pseudo-HP 283 74.2 (24.6) 44.9 (43.8) 58.1 (26.9) 50.7 (27.2) 42.2 (22.9) 68.5 (27.3) 65.1 (42.5) 70.5 (19.5) 283 6.5 (4.4) 4.8 (4.1) 11.4 (7.7)
Normative 2311 87.2 (18.7) 77.9 (35.8) 75.1 (26.0) 76.8 (22.0) 60.0 (20.8) 85.5 (22.2) 81.6 (32.4) 78.8 (16.5) 58 784 4.2 (3.3) 3.4 (3.0) 7.5 (5.5)
Females
HP and pseudo-HP 212 72.4 (25.1) 43.1 (43.6) 56.4 (26.5) 49.3 (27.3) 40.4 (23.0) 67.6 (26.9) 66.3 (42.2) 70.0 (19.1) 212 6.7 (4.3) 4.8 (4.0) 11.5 (7.6)
Normative 1184 84.8 (20.8) 75.4 (37.7) 73.0 (26.6) 76.3 (22.5) 56.9 (21.2) 83.7 (23.1) 79.1 (34.6) 77.6 (17.0)
Males
HP and pseudo-HP 71 79.6 (22.0) 50.4 (44.3) 63.0 (27.5) 54.8 (26.6) 47.2 (22.2) 71.2 (28.5) 61.3 (43.4) 72.3 (20.6) 71 5.9 (4.5) 5.0 (4.7) 10.9 (8.2)
Normative 1085 89.8 (15.5) 80.5 (33.6) 77.2 (25.0) 77.4 (21.3) 63.2 (19.9) 87.6 (20.9) 84.5 (29.7) 80.0 (15.8)
HP subgroups
Surgical 197 72.2 (24.4) 39.2 (43.1) 55.3 (26.0) 48.7 (27.1) 40.0 (22.6) 67.4 (27.4) 63.9 (42.8) 70.2 (19.0) 197 6.6 (4.3) 5.2 (4.0) 11.8 (7.7)
Nonsurgical 69 73.5 (25.9) 58.6 (43.7) 63.8 (27.7) 52.5 (26.6) 46.4 (23.3) 71.6 (25.5) 68.7 (41.7) 71.8 (20.7) 69 6.3 (4.6) 4.0 (4.3) 10.3 (7.7)
Pseudo-HP 16 86.6 (16.4) 56.3 (39.3) 64.9 (29.5) 64.3 (26.0) 47.5 (20.5) 66.4 (32.5) 62.5 (43.7) 67.5 (22.5) 16 7.0 (4.0) 4.5 (4.6) 11.5 (8.1)
Abbreviations: BP, bodily pain; SF, social functioning; RE, role limitations due to emotional problems; MH, mental health.
Normative data: SF-36: Loge and Kaasa (22) and HADS: HUNT databank (23). The overall SF-36 scores and the scores of postsurgical and
nonsurgical patients were significantly different from normative data because the CIs do not overlap. The scores among pseudo-HP were
significantly different from the normative scores for three dimensions (RP, VT, SF). Overall HAD scores and postsurgical HAD scores were
significantly different from normative data, for nonsurgical HP significantly different for anxiety, and for pseudo-HP significant different for
depression.
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tem and probably the adrenal cortex, and lack of PTH
action in tissues not related to calcium homeostasis or
bone metabolism may explain the reduced HRQOL. If so,
PTH replacement therapy should improve HRQOL; in-
deed, some PTH intervention studies show convincing im-
provement (29, 31, 34). Neither the large placebo-con-
trolled study REPLACE nor a Danish study found such
improvement (30, 35, 36), but in the Danish study many
patients became hypercalcemic because of a high fixed
PTH dose. The uncertainty about effectiveness of PTH
treatment may be due to dose or delivery, which so far has
not restored physiological calcium homeostasis properly.
Our study revealed a higher percentage of patients with
clinically significant anxiety and depression than other
disease groups in Norway, which have been studied using
HADS (37, 38). Although not directly comparable, our
results are in concordance with the result from one study
among 25 postsurgical HP patients (39).
The large sample size and the study design as a national
study without major selection bias is the greatest strength
of this study. The added inclusion criterion with need of
permanent treatment for HP for more than 1 year for pa-
tients with postsurgical HP and HP resulting from Di-
George syndrome ensured that only patients with perma-
nent HP were included. A limitation is that even though
the overall sample size is large, it constitutes a very het-
erogeneous group. The response rate of 55% in the patient
survey should ideally have been higher, but the basic char-
acteristics of the respondents and identified patients were
not significantly different; we therefore believe that this
group is representative. Furthermore, the response among
the patients who comprise the largest subgroups of the
cohort (postsurgical, APS-1, ADH) were higher than for
the patients within the smaller subgroups. The HRQOL
data were not adjusted for age and sex because the raw
data from the normative were not available for direct com-
parison. However, the age and sex distributions in the
patient populations were comparable to the normative
population. For each age and sex stratification, the trends
were similar as in the overall data, but not necessarily
significantly different because of small numbers in each
group.
In conclusion, the prevalence of genetic, autoimmune,
and idiopathic HP in Norway is higher than reported else-
where, whereas the prevalence of postsurgical HP is lower
than expected. Systematic assessment of the underlying
cause of HP is important to tailor the treatment, especially
for patients with ADH, and to identify other syndrome
components early in APS-1, DiGeorge syndrome, and
HDR. Still, many patients have unknown cause. Despite
conventional calcium, magnesium, and vitamin D supple-
mentation, complications such as kidney failure and re-
duced HRQOL are common, indicating a need for im-
provement of the therapy.
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